文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

半剂量与半光斑光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变。

Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.

机构信息

Clinica Oculistica Università di Genova, Dipartimento di Neuroscienze, Oftalmologia, Genetica e Scienze Materno Infantili, Genova, Italy; Fondazione per la Macula Onlus, Genova, Italy.

Fondazione per la Macula Onlus, Genova, Italy; Clinica Oculistica - Dipartimento di Scienze Chirurgiche, Università di Torino, Torino, Italy.

出版信息

Am J Ophthalmol. 2014 May;157(5):1033-7. doi: 10.1016/j.ajo.2014.01.022. Epub 2014 Jan 30.


DOI:10.1016/j.ajo.2014.01.022
PMID:24487046
Abstract

PURPOSE: To compare the efficacy and safety of half-fluence vs half-dose photodynamic therapy (PDT) in chronic central serous chorioretinopathy (CSC). DESIGN: Multicenter retrospective comparison study. METHODS: Retrospective review of 56 patients affected by chronic CSC, including 28 patients (31 eyes) who received half-fluence PDT and 28 patients (29 eyes) who received half-dose PDT. Best-corrected visual acuity (BCVA), central foveal thickness (CFT), and resolution of subretinal fluid on optical coherence tomography at 1 and 12 months were assessed. RESULTS: The mean logMAR BCVA improved significantly (P < .001), both in the half-fluence group (from 0.187 [± 0.187] to 0.083 [± 0.164]) and in the half-dose group (from 0.126 [± 0.091] to 0.068 [± 0.091]), at 12 months, without significant difference between the 2 groups. At 1 month a complete resolution of subretinal fluid was observed in 19 half-fluence-treated eyes (61.3%) and in 25 half-dose-treated eyes (86.2%) (P = .04). At 12 months, a complete resolution of subretinal fluid was achieved in 26 half-fluence-treated eyes (83.9%) and 29 half-dose-treated eyes (100%) (P = .0529). Nine eyes (29%) in the half-fluence group and 5 eyes (17.2%) in the half-dose group had at least 1 recurrence of subretinal fluid during the follow-up. Overall there were 15 and 5 recurrences in the half-fluence PDT and half-dose PDT groups, respectively (P = .07). In no eye of either groups was atrophy of the retinal pigment epithelium observed in the area of treatment. CONCLUSION: Half-dose PDT induced a more rapid reabsorption of the fluid, a more lasting effect, and equal safety with respect to half-fluence PDT.

摘要

目的:比较半剂量与半强度光动力疗法(PDT)治疗慢性中心性浆液性脉络膜视网膜病变(CSC)的疗效和安全性。 设计:多中心回顾性比较研究。 方法:回顾性分析 56 例慢性 CSC 患者,其中 28 例(31 眼)接受半强度 PDT 治疗,28 例(29 眼)接受半剂量 PDT 治疗。评估最佳矫正视力(BCVA)、中心视网膜厚度(CFT)和光学相干断层扫描(OCT)上 1 个月和 12 个月时视网膜下液的分辨率。 结果:两组患者的平均 logMAR BCVA 均显著提高(P<0.001),半强度组(从 0.187[±0.187]提高至 0.083[±0.164])和半剂量组(从 0.126[±0.091]提高至 0.068[±0.091]),但两组间无显著差异。1 个月时,半强度治疗组 19 只眼(61.3%)和半剂量治疗组 25 只眼(86.2%)的视网膜下液完全消退(P=0.04)。12 个月时,半强度治疗组 26 只眼(83.9%)和半剂量治疗组 29 只眼(100%)的视网膜下液完全消退(P=0.0529)。半强度治疗组 9 只眼(29%)和半剂量治疗组 5 只眼(17.2%)在随访期间至少有 1 次视网膜下液复发。半强度 PDT 组和半剂量 PDT 组分别有 15 次和 5 次复发(P=0.07)。两组均未观察到治疗区域的视网膜色素上皮萎缩。 结论:半剂量 PDT 可更快地吸收液体,效果更持久,与半强度 PDT 相比安全性相当。

相似文献

[1]
Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.

Am J Ophthalmol. 2014-1-30

[2]
COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.

Retina. 2017-2

[3]
Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.

Ophthalmology. 2013-11-20

[4]
Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.

Graefes Arch Clin Exp Ophthalmol. 2018-11

[5]
Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.

Retina. 2013-2

[6]
Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial.

Am J Ophthalmol. 2009-11-6

[7]
A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy.

Am J Ophthalmol. 2011-7-13

[8]
Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy.

Am J Ophthalmol. 2011-10-22

[9]
Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy.

Ophthalmology. 2014-1-16

[10]
A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial.

JAMA Ophthalmol. 2015-3

引用本文的文献

[1]
Impact of global shortage of verteporfin (visudyne) on photodynamic therapy.

Oman J Ophthalmol. 2025-6-24

[2]
Treatment of central serous chorioretinopathy: new options for an old disease.

Eye (Lond). 2025-7-4

[3]
Photodynamic treatment without verteporfin in chronic central serous chorioretinopathy.

BMC Ophthalmol. 2025-5-23

[4]
Therapeutic interventions for chronic central serous chorioretinopathy: a comprehensive assessment of systematic reviews.

Int J Retina Vitreous. 2025-3-23

[5]
Oscillatory photodynamic therapy in central serous chorioretinopathy.

Graefes Arch Clin Exp Ophthalmol. 2025-2-11

[6]
Influence of scleral thickness on photodynamic therapy outcomes in central serous chorioretinopathy.

Acta Ophthalmol. 2025-5

[7]
Fluorescein versus Indocyanine Green Angiography Guided Half-Dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.

J Ophthalmic Vis Res. 2024-3-14

[8]
Wide-Field Choroidal Thickness Analysis after Half-Fluence Photodynamic Therapy Combined with Intravitreal Aflibercept Injection in Pachychoroid Neovasculopathy.

J Clin Med. 2024-3-11

[9]
Acute Central Serous Chorioretinopathy Outbreak during the COVID-19 Pandemic: A Pilot Study.

Medicina (Kaunas). 2024-1-9

[10]
Half-dose photodynamic therapy versus 577 nm subthreshold pulse laser therapy in treatment-naive patients with central serous chorioretinopathy.

BMC Ophthalmol. 2024-1-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索